What's breaking now, across thousands of outlets.
OpenEvidence is booming despite questions about accuracy and ads.
We haven't written up this one. Ars Technica Health has the full story — the link below goes straight to it.
In 2024, I started Endpoints News’ flagship AI event because I didn’t see anything like it. Biopharma conferences scratched the surface with a stray AI panel.
China’s exports are surging, driven by AI-related technologies. National security-driven export bans could change that.
